[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649440":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":55,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":26,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":33,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Clínica Dávila","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Buprenorphine Patch","EXPERIMENTAL","Participants will receive a 5 mcg\u002Fhour transdermal buprenorphine patch before surgery in addition to standard multimodal analgesia.",[13],"Drug: Buprenorphine (BUP)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Patch","PLACEBO_COMPARATOR","Participants will receive a placebo transdermal patch before surgery in addition to standard multimodal analgesia.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Buprenorphine (BUP)","Transdermal buprenorphine patch (5 mcg\u002Fhour) administered preoperatively as part of multimodal analgesia.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo transdermal patch identical in appearance to the active patch and administered preoperatively as part of multimodal analgesia.",[15],[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Santiago","Santiago Metropolitan","8431657","Chile","CL",{"type":40,"coordinates":41},"Point",[42,43],-70.64827,-33.45694,{"lat":43,"lon":42},[46,51],{"name":47,"role":48,"phone":49,"phoneExt":26,"email":50},"Alejandra Sofía Rivera, MsC Epidemiology","CONTACT","930363776","alejandra.rivera@davila.cl",{"name":52,"role":48,"phone":53,"phoneExt":26,"email":54},"Bernarda Miranda, Bibliotecary","+56930363776","bmiranda@davila.cl",{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100649440","analgesia-with-transdermal-buprenorphine-patch-in-adults-undergoing-video-assisted-thoracoscopic-surgery-100649440",false,"NCT07733128","Analgesia With Transdermal Buprenorphine Patch in Adults Undergoing Video-Assisted Thoracoscopic Surgery","Analgesia With a 5 mcg\u002FHour Transdermal Buprenorphine Patch as Part of Multimodal Analgesia in Adults Undergoing Unilateral Video-Assisted Thoracoscopic Surgery: A Triple-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Scheduled for elective unilateral video-assisted thoracoscopic surgery (VATS).\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to buprenorphine or any component of the transdermal patch.\n* Chronic opioid use before surgery.\n* Severe hepatic impairment.\n* Pregnancy or breastfeeding.\n* Inability to complete postoperative pain assessments.\n* Any condition that, in the investigator's opinion, could interfere with study participation or outcome assessment.","ALL","18 Years",{"count":67,"type":68},90,"ESTIMATED","INTERVENTIONAL",[71],"NA","Postoperative pain remains a major challenge after video-assisted thoracoscopic surgery (VATS), despite the use of multimodal analgesia. This randomized, triple-blind, placebo-controlled clinical trial will evaluate whether adding a 5 mcg\u002Fhour transdermal buprenorphine patch to the standard multimodal analgesic regimen reduces postoperative pain in adults undergoing unilateral VATS. Participants will be randomly assigned to receive either transdermal buprenorphine or placebo in addition to standard analgesia. Postoperative pain will be assessed at 24, 48, and 72 hours and 7 days after surgery. Secondary outcomes include opioid rescue requirements, length of hospital stay, postoperative nausea and vomiting, pruritus, and urinary retention.",[74,75,76],"Postoperative Pain","Thoracic Surgery","Video-Assisted Thoracoscopic Surgery",[78,79,80,76,81,74,82,75,83,84],"Buprenorphine","Transdermal Patch","Multimodal Analgesia","VATS","Randomized Controlled Trial","Acute Pain","Opioid Analgesia","2026-07-24",{"date":87,"type":88},"2026-07-29","ACTUAL",{"date":90,"type":88},"2026-03-01",{"date":92,"type":68},"2027-07",{"name":5,"class":6},1]